Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P697: Thiopurines vs. anti-TNFa for the prevention of postoperative recurrence in Crohn’s disease—a meta-analysisECCO '18 Vienna
Year: 2018
Authors:

E.M.J. Beelen1*, B. Oldenburg2, A.E. van der Meulen-de Jong3, C.I.J. Ponsioen4, G. Dijkstra5, M.J. Pierik6, F. Hoentjen7, N.K.H. de Boer8, N.S. Erler9, C.J. van der Woude1, A.C. de Vries1

1Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands, 3Leiden University Medical Center, Department of Gastroenteorlogy and Hepatology, Leiden, The Netherlands, 4Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 5University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, 6Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, The Netherlands, 7Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands, 8VU University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 9Erasmus MC, Department of Biostatistics, Rotterdam, The Netherlands

P698: Early dose optimisation in non-responders to golimumab induction treatment for ulcerative colitis is supported by pharmacokinetic dataECCO '18 Vienna
Year: 2018
Authors:

G. Philip1, C. Marano2, J. Adedokun2, R. Melsheimer3, F. Cornillie4*

1Merck & Co., Inc., Kenilworth, USA, 2Janssen Research and Development, LLC, Spring House, PA, USA, 3Janssen Biologics BV, Leiden, The Netherlands, 4Merck Sharpe and Dohme, Kriens, Switzerland

P699: Radiologic response reduces the risk of small-bowel surgery in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

E. Hallé1*, M. Azahaf1, N. Duveau2, M. Nachury1, J. Branche1, R. Gerard1, P. Wils1, P. Desreumaux1, O. Ernst1, B. Pariente1

1Hopital Claude Huriez, Lille, France, 2Hopital de Roubaix, Roubaix, France

P700: A high CRP before surgery and early medical prophylaxis predict postoperative endoscopic Crohn’s disease recurrenceECCO '18 Vienna
Year: 2018
Authors:

S. Sooben1, L. Thin1*, S. Picardo2, B. Mackinnon3, J. Ryan4, M.H. Wallace4,5

1Fiona Stanley Hospital, Department of Gastroenterology, Perth, Australia, 2Royal Perth Hospital, Department of Gastroenterology, Perth, Australia, 3Insitute of Immunology and Infectious Diseases, Murdoch University, Statistics, Perth, Australia, 4Fiona Stanley hospital, Colorectal surgery, Perth, Australia, 5University of Western Australia, School of Medicine and Pharmacology, Perth, Australia

P701: Quality of life of patients with inflammatory bowel diseases who live with an ostomy: Results of a French national surveyECCO '18 Vienna
Year: 2018
Authors:

G. Pineton de Chambrun1*, M. Liberatore2, A. Buisson2, P. Blanc1, A. Olympie2

1Montpellier University Hospital, Gastroenterology, Montpellier, France, 2Association François Aupetit, Paris, France

P702: Head-to-head comparison of biological drugs in the treatment of ulcerative colitis: Suggestions from a real-life, inception cohort, single-centre study on consecutive post-marketing treatmentsECCO '18 Vienna
Year: 2018
Authors:

A. Cassinotti1, N. Mezzina1*, A. Massari1, S. Grillo2, S. Ardizzone1

1ASST Fatebenefratelli Sacco, DIBIC “L. Sacco” University of Milan, Gastrointestinal Unit, Milan, Italy, 2University Hospital of Parma, Department of Gastroenterology and Digestive Endoscopy, Parma, Italy

P703: Clinical, radiographic and endoscopic remission with vedolizumab treatment in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

P.G. Kotze*, C. Ma, A. Almutairdi, A. Al-Damarki, S. Devlin, G. Kaplan, C. Seow, K. Novak, C. Lu, J. Ferraz, M. Stewart, M. Buresi, M. Mathivanan, H. Jijon, J. Heatherington, M.-L. Martin, R. Panaccione

University of Calgary, IBD unit, division of Gastroenterology and Hepatology, Calgary, Canada

P704: Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

B. Verstockt1,2*, M. Noman1, I. Aerden1, M. Peeters3, E. Brouwers3, V. Ballet1, L. Vandersmissen1,3, G. Van Assche1,2, A. Gils3, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

P705: Switching from originator to biosimilar infliximab—real-world data from 18 months prospective follow-up of a single-centre IBD populationECCO '18 Vienna
Year: 2018
Authors:

M.L. Hoivik1*, L.C. Buer1,2, N. Bolstad3, B. Moum1,2, A.W. Medhus1

1Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 2University of Oslo, Faculty of Medicine, Oslo, Norway, 3Oslo University Hospital, Department of Medical Biochemistry, Oslo, Norway

P706: Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapyECCO '18 Vienna
Year: 2018
Authors:

J. Kovacs1*, B. Kadleckova2, L. Gombosova3, L. Novotna4, E. Barlova4, J. Lucenincova5, P. Mikus6, M. Zakuciova3, Z. Zelinkova1

1St Michael`s Hospital, Department of Gastroenterology, Bratislava, Slovakia, 2Assiduo, IBD Center, Bratislava, Slovakia, 3University Hospital Louis Pasteur, 1st Department of Internal Medicine, Kosice, Slovakia, 4University Hospital Louis Pasteur, Department of Laboratory Medicine, Bratislava, Slovakia, 5St Michael`s Hospital, Department of Biochemistry, Bratislava, Slovakia, 6Comenius University, Faculty of Pharmacy, Bratislava, Slovakia

P707: Increasing abundance of faecalibacterium prausnitzii is associated with decreased intestinal inflammation in Crohn’s disease: A longitudinal studyECCO '18 Vienna
Year: 2018
Authors:

O. Björkqvist1*, D. Repsilber2, M. Seifert3, L. Engstrand3, I. Rangel2, J. Halfvarson2

1Örebro Universitet, School of Medical Sciences, Örebro Universitet, Sweden, 2Örebro Universitet, Örebro, Sweden, 3Karolinska Institutet, Microbiology, Tumor and Cell Biology, Stockholm, Sweden

P708: Home-based infusion therapy for biologic agent administration as a therapeutic option for patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

M. Madden, S. S. R. Pulusu*, I. Lawrance

Centre for Inflammatory Bowel Disease, St John of God Subiaco Hospital, Perth, Australia

P709: Is there a difference in adalimumab drug levels according to pen vs. syringe use: An international, multi-centre retrospective analysisECCO '18 Vienna
Year: 2018
Authors:

R. Little1*, I. Chu1, E. van der Zanden2, E. Flanagan3, S. Bell3, M. Sparrow1, E. Shelton4, S. Connor2, X. Roblin5, M. Ward1

1Alfred Health and Monash University, Gastroenterology, Melbourne, Australia, 2Liverpool Hospital and University of New South Wales, Gastroenterology, Sydney, Australia, 3St. Vincent's Hospital and University of Melbourne, Gastroenterology, Melbourne, Australia, 4Monash Health and Monash University, Gastroenterology, Mebourne, Australia, 5CHU Saint-Etienne, Gastro-entérologie et Hépatologie, Saint-Etienne, France

P710: Efficacy of therapeutic intervention for ulcerative colitis patients with the Mayo Endoscopic Score of 1ECCO '18 Vienna
Year: 2018
Authors:

T. Fukuda1*, M. Naganuma1, S. Sugimoto1, K. Ono1, K. Nanki1, S. Mizuno1, K. Kimura2, M. Mutaguchi1, K. Takabayashi2, N. Inoue3, H. Ogata2, Y. Iwao3, T. Kanai1

1Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan, 2Keio University School of Medicine, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan, 3Keio University School of Medicine, Center for Preventive Medicine, Tokyo, Japan

P711: A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of responseECCO '18 Vienna
Year: 2018
Authors:

S. Restellini1,2*, T. Bessissow1, C. Lemieux1, C.-Y. Chao1,3, G. Wild1, E. Seidman1, A. Bitton1, P.L. Lakatos1,4, W. Afif1

1McGill University Health Centre, Gastroenterology, Montreal, Canada, 2Division of Gastroenterology and Hepatology, Department of Medical Specialties, Geneva, Switzerland, 3Princess Alexandra Hospital, Department of Gastroenterology and Hepatology, Brisbane, Australia, 4Semmelweis University, 1st Department of Medicine, Budapest, Hungary

P712: Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modellingECCO '18 Vienna
Year: 2018
Authors:

S. Doshi*, E. Krishnan, H. Wang, N. Zhang, V. Chow

Amgen Inc., Biosimilars, Thousand Oaks, USA

P713: Home-based vedolizumab infusions: A suitable alternative to routine hospital infusionsECCO '18 Vienna
Year: 2018
Authors:

N. Peek-Kuijt1*, J. Nieuwstraten1, L. van Ginkel2, J. Maljaars1, A. van der Meulen- de Jong1

1Leiden University Medical Center, Gastroenterology, Leiden, The Netherlands, 2Leiden University Medical Center (LUMC), Care Registration, Leiden, The Netherlands

P714: Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patientsECCO '18 Vienna
Year: 2018
Authors:

M. Iborra1*, N. Maroto2, P. Navarro-Cortes3, B. Beltran1, M. Boscá-Watts3, I. Ferrer2, N. Garcia-Morales1, E. Sáez-González1, J. Hinojosa2, M. Minguez3, P. Nos1

1La Fe University and Polytechnic Hospital and CIBER-EHD, Department of Gastroenterology, Valencia, Spain, 2Hospital de Manises, Department of Gastroenterology, Manises, Spain, 3University Clinic Hospital of Valencia, Department of Gastroenterology and Hepatology, Valencia, Spain

P715: Opioid use in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

X. Lin, J. Lofland, L. Zhang, K. Lee, S. Sloan*, L. Chamaa, C. Marano, S. Plevy

Janssen Research and Development, LLC, Spring House, USA

P716: Current smoking trends in British IBD patients in the age of e-cigarettesECCO '18 Vienna
Year: 2018
Authors:

K. Loonat, R. Sagar, C. Selinger*

St James University Hospital, Gastroenterology, Leeds, UK